Tech Company Financing Transactions
Allakos Funding Round
Allakos closed a $17.9 million venture capital round on 3/26/2015. Investors included private investors.
Transaction Overview
Company Name
Announced On
3/26/2015
Transaction Type
Venture Equity
Amount
$17,949,545
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for investment details, if applicable. Not an offer or solicitation for sale of securities.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
975 Island Dr. 201
Redwood City, CA 94065
USA
Redwood City, CA 94065
USA
Phone
Website
Email Address
Overview
Allakos (Nasdaq: ALLK) is a biotechnology company developing antibodies targeting receptors that modulate the activity of immune effector cells involved in inflammation and tissue damage.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Alexander
Chief Medical Officer
Henrik Rasmussen
Chief Operating Officer
Adam Tomasi
VP - Bus. Development
Simon Greenwood
VP - General Counsel
Mark Asbury
VP - Regulatory Affairs
Sally Bolmer
Browse more venture capital transactions:
Prev: 3/26/2015: Char Software venture capital transaction
Next: 3/26/2015: 6fusion venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs